PSMA PET Imaging May Offer Key Prognostic Markers for Prostate Cancer
For patients initially diagnosed with non-metastatic, castration-resistant prostate cancer, pelvic lymph node involvement and five or more polymetastases detected with prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are significantly associated with lower overall survival rates, according to recently presented research at the American Society of Clinical Oncology (ASCO) conference.
New research suggests that pelvic lymph node involvement and polymetastatic disease detected by prostate-specific membrane antigen (PSMA)/ positron emission tomography (PET) are associated with a significantly worse prognosis in patients initially diagnosed with non-metastatic castration-resistant prostate cancer (nmCRPC).
In multicenter research presented at the American Society of Clinical Oncology (ASCO) conference and recently published in the Journal of Clinical Oncology, researchers reviewed PSMA/PET scans for 200 patients who were initially diagnosed via conventional imaging with nmCRPC. These patients also had an International Society of Urological Pathology (ISUP) grade 4 or higher, and/or a prostate-specific antigen doubling time (PSADT less than or equal to 10 months, according to the study.
The study authors found that polymetastatic disease (five or more polymetastases) on PSMA PET imaging had a 1.93 hazard ratio (HR). While the median overall survival rate and metastases-free survival rate (nMFS) for the cohort were 74 months and 60 months, respectively, the researchers found that those with polymetstatic disease had a median overall survival rate of 61 months and a 38-month nMFS.
Initial pelvic lymph node involvement had no impact on the nMFS rate, according to the study authors. However, they did note a significant association with a shorter mean overall survival rate (2.01 HR). Patients with initial pelvic lymph node involvement had a median overall survival rate of 55 months in comparison to the aforementioned 74-month overall survival rate in the cohort.
“PSMA-PET disease extent provides a potential novel additional risk stratification for (patients) with nmCRPC without distant metastasis based on conventional imaging,” wrote Wolfgang Fendler, M.D., who is affiliated with the Department of Nuclear Medicine at the University of Duisburg-Essen and the German Cancer Consortium (DKTK) at University Hospital Essen in Essen, Germany, and colleagues.
While the researchers noted a 1.58 HR in patients with prior definitive radiotherapy (RT) and a 1.41 HR for those with a Gleason grade greater than or equal to eight, they noted these factors had no significant impact on overall survival rates. The PSA level and PSADT also had no impact on survival rates, according to the study authors.
(Editor’s note: For related content, see “Emerging Nomogram May Predict Outcomes After PSMA PET-Guided Salvage Radiotherapy in Patients with Prostate Cancer” and “FDA Approves New PSMA PET Agent POSLUMA for Prostate Cancer Imaging.”)
Meta-Analysis Shows No Difference Between bpMRI and mpMRI in Ruling Out csPCa
March 6th 2025In an 18-study meta-analysis involving over 4,600 patients, researchers found that bpMRI and mpMRI had equivalent pooled negative predictive value (NPV) of 92 percent for clinically significant prostate cancer (csPCa).
Can Deep Learning Ultra-Fast bpMRI Have an Impact in Prostate Cancer Imaging?
March 3rd 2025A deep learning-enhanced ultra-fast bpMRI protocol offered similar sensitivity for csPCa as mpMRI with an 80 percent reduction in scan time, according to research findings presented at the European Congress of Radiology (ECR) conference.
ECR Mammography Study: Pre-Op CEM Detects 34 Percent More Multifocal Masses than Mammography
February 28th 2025In addition to contrast-enhanced mammography (CEM) demonstrating over a 90 percent detection rate for multifocal masses, researchers found that no significant difference between histological measurements and CEM, according to study findings presented at the European Congress of Radiology.
Emerging AI Software for Prostate MRI Offers 95 Percent Sensitivity for csPCa
February 28th 2025In a multicenter study involving over 1,000 patients, a deep learning software offered comparable sensitivity and specificity for Gleason grade group > 2 tumors in comparison to radiologist interpretation.
